European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact
Guidelines

Testicular Cancer

Want to read the guideline in your own time? Download the PDF

Download full guideline

Looking for a quick overview? Check the pocket guidelines.

Download pocket guidelines
Full text guidelineSummary of ChangesPublications & AppendicesPanelRelated content
No results found
  1. Introduction
  2. Methods
  3. Epidemiology Aetiology Pathology
  4. Staging & Prognosis
  5. Diagnostic Evaluation
  6. Disease Management
  7. Follow Up After Curative Therapy
  8. Rare Adult Para And Testicular Tumours
  9. References
  10. Conflict Of Interest
  11. Citation Information
  12. Copyright And Terms Of Use
2. Methods
  • 1. Introduction
  • 2. Methods
  • 3. Epidemiology Aetiology Pathology
  • 4. Staging Prognosis
  • 5. Diagnostic Evaluation
  • 6. Disease Management
  • 7. Follow Up After Curative Therapy
  • 8. Rare Adult Para And Testicular Tumours
  • 9. References
  • 10. Conflict Of Interest
  • 11. Citation Information
  • 12. Copyright And Terms Of Use
  • No elements found. Consider changing the search query.
  • List is empty.

2. METHODS

2.1. Introduction

The 2025 edition of the TC Guidelines is a reprint of the 2024 version. For the 2024 EAU Guidelines on TC, new and relevant evidence was identified, collated and appraised through a structured assessment of the literature. A broad and comprehensive literature search, covering all sections of the TC Guidelines was performed. The search was limited to studies representing high levels of evidence, i.e., systematic reviews (SRs) with meta-analysis, randomised controlled trials (RCTs), and prospective non-randomised comparative studies, published in the English language. Databases searched included Medline, EMBASE, and the Cochrane Libraries, covering a time frame between May 1st 2021 and May 1st 2023. A total of 1,867 unique records were identified, retrieved and screened for relevance.

Detailed search strategies for the 2024 guideline are available online: 
https://uroweb.org/guidelines/testicular-cancer/publications-appendices

Recommendations within the Guidelines are developed by the panels to prioritise clinically important care decisions. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and the nature and variability of patient values and preferences. This decision process, which can be reviewed in the strength rating forms which accompany each guideline statement, addresses a number of key elements:

  1. the overall quality of the evidence which exists for the recommendation [2];
  2. the magnitude of the effect (individual or combined effects);
  3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
  4. the balance between desirable and undesirable outcomes;
  5. the impact and certainty of patient values and preferences on the intervention.

Strong recommendations typically indicate a high degree of evidence quality and/or a favourable balance of benefit to harm and patient preference. Weak recommendations typically indicate availability of lower quality evidence, and/or equivocal balance between benefit and harm, and uncertainty or variability of patient preference [3].

Additional information can be found in the general Methodology section of this print, and online at the EAU website: https://uroweb.org/guidelines.

A list of associations endorsing the EAU Guidelines can also be viewed online at the above address.

2.2. Review

The 2020 Guidelines document was subjected to peer-review following publication. The next peer-review is scheduled for 2025.

2.3. Future goals

  • A collaborative SR on hypogonadism following orchidectomy with the EAU Male Sexual Health guidelines panel;
  • The development of a TC survivorship plan in collaboration with patient associations;
  • Care Pathways on diagnostic, treatment clinical stage (CS) 1, and treatment of metastatic disease;
  • Collaboration with the patient office and patient representatives to develop a care pathway focusing on what the patient needs to know from diagnosis through to follow-up.
About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer